{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:00:28Z","timestamp":1793437228168,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pulsed-field ablation (PFA) has shown favourable data in terms of safety and procedural efficiency for pulmonary vein isolation (PVI). We sought to compare procedural and 1-year follow-up data of patients with paroxysmal atrial fibrillation (AF) undergoing PVI using PFA, cryoballoon ablation (CBA) and radiofrequency ablation (RFA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Consecutive patients with paroxysmal AF undergoing a first PVI with PFA at our institution were included. For comparison, patients with paroxysmal AF undergoing a first PVI with CBA and RFA were selected using a 1:2:2 propensity score matching. The PFA group followed the standard 32-applications lesion-set protocol, the CBA group a time-to-effect plus 2-min strategy, and the RFA group the CLOSE protocol. Patients were followed with 7d-Holter ECGs 3, 6, and 12\u00a0months after ablation. The primary endpoint was recurrence of atrial tachyarrhythmia (ATa) following a blanking period of 3\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 200 patients were included (PFA<jats:italic> n<\/jats:italic>\u2009=\u200940; CBA <jats:italic>n<\/jats:italic>\u2009=\u200980; RFA <jats:italic>n<\/jats:italic>\u2009=\u200980). Median procedure times were shortest with CBA (75\u00a0min) followed by PFA (94\u00a0min) and RFA (182\u00a0min<jats:italic>; p<\/jats:italic>\u2009&lt;\u20090.001). Fluoroscopy dose was lowest with RFA (1.6Gycm<jats:sup>2<\/jats:sup>) followed by PFA (5.0Gycm<jats:sup>2<\/jats:sup>) and CBA (5.7Gycm<jats:sup>2<\/jats:sup>; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). After a 1-year follow-up, freedom from ATa recurrence was 85.0% with PFA, 66.2% with CBA and 73.8% with RFA (<jats:italic>p<\/jats:italic>\u2009=\u20090.12 PFA vs. CBA; <jats:italic>p<\/jats:italic>\u2009=\u20090.27 PFA vs. RFA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a propensity score matched analysis of patients with paroxysmal AF, freedom from any ATa 1\u00a0year after PVI using PFA was favourable and at least as good as for PVI with CBA or RFA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s10840-023-01651-4","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T06:02:06Z","timestamp":1696053726000},"page":"389-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Pulsed-field vs. cryoballoon vs. radiofrequency ablation: a propensity score matched comparison of one-year outcomes after pulmonary vein isolation in patients with paroxysmal atrial fibrillation"],"prefix":"10.1007","volume":"67","author":[{"given":"Jens","family":"Maurhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kueffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Madaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Stettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Stefanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Kozhuharov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Galuszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Servatius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Haeberlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Noti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Roten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7197-8415","authenticated-orcid":false,"given":"Tobias","family":"Reichlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"issue":"14","key":"1651_CR1","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jacc.2020.02.025","volume":"75","author":"MK Chung","year":"2020","unstructured":"Chung MK, Refaat M, Shen WK, Kutyifa V, Cha YM, Di Biase L, et al. Atrial fibrillation: JACC Council Perspectives. J Am Coll Cardiol. 2020;75(14):1689\u2013713.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"1651_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacc.2012.11.064","volume":"61","author":"DL Packer","year":"2013","unstructured":"Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(16):1713\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1651_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/jama.2009.2029","volume":"303","author":"DJ Wilber","year":"2010","unstructured":"Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303(4):333\u201340.","journal-title":"JAMA"},{"issue":"24","key":"1651_CR4","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1161\/CIRCULATIONAHA.108.772582","volume":"118","author":"P Ja\u00efs","year":"2008","unstructured":"Ja\u00efs P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118(24):2498\u2013505.","journal-title":"Circulation"},{"issue":"1","key":"1651_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jacep.2017.06.023","volume":"4","author":"P Taghji","year":"2018","unstructured":"Taghji P, El Haddad M, Phlips T, Wolf M, Knecht S, Vandekerckhove Y, et al. Evaluation of a strategy aiming to enclose the pulmonary veins with contiguous and optimized radiofrequency lesions in paroxysmal atrial fibrillation: a pilot study. JACC Clin Electrophysiol. 2018;4(1):99\u2013108.","journal-title":"JACC Clin Electrophysiol"},{"issue":"7","key":"1651_CR6","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jacc.2014.04.072","volume":"64","author":"A Natale","year":"2014","unstructured":"Natale A, Reddy VY, Monir G, Wilber DJ, Lindsay BD, McElderry HT, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol. 2014;64(7):647\u201356.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1651_CR7","doi-asserted-by":"publisher","first-page":"e005318","DOI":"10.1161\/CIRCEP.117.005318","volume":"10","author":"\u00c1 Ferrero-de-Loma-Osorio","year":"2017","unstructured":"Ferrero-de-Loma-Osorio \u00c1, Garc\u00eda-Fern\u00e1ndez A, Castillo-Castillo J, Izquierdo-de-Francisco M, Ib\u00e1\u00f1ez-Cr\u00edado A, Moreno-Arribas J, et al. Time-to-effect-based dosing strategy for cryoballoon ablation in patients with paroxysmal atrial fibrillation: results of the plusONE Multicenter Randomized Controlled Noninferiority Trial. Circ Arrhythm Electrophysiol. 2017;10(12):e005318.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"22","key":"1651_CR8","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1161\/CIRCULATIONAHA.119.042622","volume":"140","author":"JG Andrade","year":"2019","unstructured":"Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation. 2019;140(22):1779\u201388.","journal-title":"Circulation"},{"issue":"2","key":"1651_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2212540","volume":"388","author":"JG Andrade","year":"2023","unstructured":"Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med. 2023;388(2):105\u201316.","journal-title":"N Engl J Med"},{"issue":"3","key":"1651_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10840-020-00734-w","volume":"60","author":"A Natale","year":"2021","unstructured":"Natale A, Mohanty S, Goldstein L, Gomez T, Hunter TD. Real-world safety of catheter ablation for atrial fibrillation with contact force or cryoballoon ablation. J Interv Card Electrophysiol. 2021;60(3):445\u201352.","journal-title":"J Interv Card Electrophysiol"},{"issue":"3","key":"1651_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jacc.2019.04.021","volume":"74","author":"VY Reddy","year":"2019","unstructured":"Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019;74(3):315\u201326.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1651_CR12","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jacc.2020.07.007","volume":"76","author":"VY Reddy","year":"2020","unstructured":"Reddy VY, Anic A, Koruth J, Petru J, Funasako M, Minami K, et al. Pulsed field ablation in patients with persistent atrial fibrillation. J Am Coll Cardiol. 2020;76(9):1068\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1651_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jacep.2021.02.014","volume":"7","author":"VY Reddy","year":"2021","unstructured":"Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7(5):614\u201327.","journal-title":"JACC Clin Electrophysiol"},{"issue":"2","key":"1651_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10439-005-8981-8","volume":"33","author":"RV Davalos","year":"2005","unstructured":"Davalos RV, Mir ILM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223\u201331.","journal-title":"Ann Biomed Eng"},{"issue":"5","key":"1651_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1109\/MEI.2012.6268438","volume":"28","author":"T Kotnik","year":"2012","unstructured":"Kotnik T, Kramar P, Pucihar G, Miklavcic D, Tarek M. Cell membrane electroporation- Part 1: The phenomenon. IEEE Electr Insul Mag. 2012;28(5):14\u201323.","journal-title":"IEEE Electr Insul Mag"},{"issue":"8","key":"1651_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jacep.2018.06.005","volume":"4","author":"FHM Wittkampf","year":"2018","unstructured":"Wittkampf FHM, van Es R, Neven K. Electroporation and its relevance for cardiac catheter ablation. JACC Clin Electrophysiol. 2018;4(8):977\u201386.","journal-title":"JACC Clin Electrophysiol"},{"issue":"8","key":"1651_CR17","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/jce.14414","volume":"31","author":"CJ Bradley","year":"2020","unstructured":"Bradley CJ, Haines DE. Pulsed field ablation for pulmonary vein isolation in the treatment of atrial fibrillation. J Cardiovasc Electrophysiol. 2020;31(8):2136\u201347.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"8","key":"1651_CR18","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.hrthm.2015.05.012","volume":"12","author":"VJHM van Driel","year":"2015","unstructured":"van Driel VJHM, Neven K, van Wessel H, Vink A, Doevendans PAFM, Wittkampf FHM. Low vulnerability of the right phrenic nerve to electroporation ablation. Heart Rhythm. 2015;12(8):1838\u201344.","journal-title":"Heart Rhythm"},{"issue":"8","key":"1651_CR19","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/europace\/euac050","volume":"24","author":"E Ekanem","year":"2022","unstructured":"Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace. 2022;24(8):1256\u201366.","journal-title":"Europace"},{"key":"1651_CR20","doi-asserted-by":"crossref","unstructured":"Turagam M, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF Registry. Circulation. 2023;148:35\u201346.","DOI":"10.1161\/CIRCULATIONAHA.123.064959"},{"issue":"5","key":"1651_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.hrthm.2021.12.028","volume":"19","author":"H Servatius","year":"2022","unstructured":"Servatius H, K\u00fcffer T, Baldinger SH, Asatryan B, Seiler J, Tanner H, et al. Dexmedetomidine versus propofol for operator-directed nurse-administered procedural sedation during catheter ablation of atrial fibrillation: A randomized controlled study. Heart Rhythm. 2022;19(5):691\u2013700.","journal-title":"Heart Rhythm"},{"issue":"8","key":"1651_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.jacep.2018.04.005","volume":"4","author":"VY Reddy","year":"2018","unstructured":"Reddy VY, Koruth J, Jais P, Petru J, Timko F, Skalsky I, et al. Ablation of atrial fibrillation with pulsed electric fields: an ultra-rapid, tissue-selective modality for cardiac ablation. JACC Clin Electrophysiol. 2018;4(8):987\u201395.","journal-title":"JACC Clin Electrophysiol"},{"issue":"8","key":"1651_CR23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/europace\/euac044","volume":"24","author":"T Kueffer","year":"2022","unstructured":"Kueffer T, Baldinger SH, Servatius H, Madaffari A, Seiler J, M\u00fchl A, et al. Validation of a multipolar pulsed-field ablation catheter for endpoint assessment in pulmonary vein isolation procedures. Europace. 2022;24(8):1248\u201355.","journal-title":"Europace"},{"issue":"9","key":"1651_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.hrthm.2017.06.020","volume":"14","author":"A Aryana","year":"2017","unstructured":"Aryana A, Kenigsberg DN, Kowalski M, Koo CH, Lim HW, O\u2019Neill PG, et al. Verification of a novel atrial fibrillation cryoablation dosing algorithm guided by time-to-pulmonary vein isolation: results from the Cryo-DOSING Study (Cryoballoon-ablation DOSING Based on the Assessment of Time-to-Effect and Pulmonary Vein Isolation Guidance). Heart Rhythm. 2017;14(9):1319\u201325.","journal-title":"Heart Rhythm"},{"issue":"23","key":"1651_CR25","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1602014","volume":"374","author":"KH Kuck","year":"2016","unstructured":"Kuck KH, Brugada J, F\u00fcrnkranz A, Metzner A, Ouyang F, Chun KRJ, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235\u201345.","journal-title":"N Engl J Med"},{"issue":"6","key":"1651_CR26","doi-asserted-by":"publisher","first-page":"e010817","DOI":"10.1161\/CIRCEP.121.010817","volume":"15","author":"B Schmidt","year":"2022","unstructured":"Schmidt B, Bordignon S, Tohoku S, Chen S, Bologna F, Urbanek L, et al. 5S Study: safe and simple single shot pulmonary vein isolation with pulsed field ablation using sedation. Circ Arrhythm Electrophysiol. 2022;15(6):e010817.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"1651_CR27","doi-asserted-by":"publisher","first-page":"e011780","DOI":"10.1161\/CIRCEP.122.011780","volume":"16","author":"M Duytschaever","year":"2023","unstructured":"Duytschaever M, De Potter T, Grimaldi M, Anic A, Vijgen J, Neuzil P, et al. Paroxysmal atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation catheter integrated with a 3-dimensional mapping system: 1-year outcomes of the multicenter inspIRE Study. Circ Arrhythm Electrophysiol. 2023;16(3):e011780.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1651_CR28","doi-asserted-by":"crossref","unstructured":"Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed Field ablation for the treatment of atrial fibrillation: PULSED AF Pivotal Trial. Circulation. 2023 Mar 6;147:00\u201300. [Epub ahead of print].","DOI":"10.1161\/CIRCULATIONAHA.123.063988"},{"issue":"1","key":"1651_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.121.056109","volume":"145","author":"M Aguilar","year":"2022","unstructured":"Aguilar M, Macle L, Deyell MW, Yao R, Hawkins NM, Khairy P, et al. Influence of monitoring strategy on assessment of ablation success and postablation atrial fibrillation burden assessment: implications for practice and clinical trial design. Circulation. 2022;145(1):21\u201330.","journal-title":"Circulation"},{"issue":"3","key":"1651_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/europace\/euaa298","volume":"23","author":"KH Kuck","year":"2021","unstructured":"Kuck KH, Lebedev DS, Mikhaylov EN, Romanov A, Gell\u00e9r L, Kal\u0113js O, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace. 2021;23(3):362\u20139.","journal-title":"Europace"},{"issue":"2","key":"1651_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/europace\/euac211","volume":"25","author":"S Tohoku","year":"2023","unstructured":"Tohoku S, Chun KRJ, Bordignon S, Chen S, Schaack D, Urbanek L, et al. Findings from repeat ablation using high-density mapping after pulmonary vein isolation with pulsed field ablation. Europace. 2023;25(2):433\u201340.","journal-title":"Europace"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-023-01651-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01651-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:11:21Z","timestamp":1709176281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-023-01651-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1007\/s10840-023-01651-4","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Local Ethics Committee, and all participants signed written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"J. S.: The spouse of Dr. Seiler is an employee of Boston Scientific and stock owner of Boston Scientific and Abbott. N. K.: Research grants from the Swiss National Science Foundation (P400PM-194477 and P5R5PM_210856), Gottfried und Julia Bangerter-Rhyner-Stiftung, Freiwillige Akademische Gesellschaft, L. & Th. La Roche Stiftung, and the European Society of Cardiology. A. H.: Travel fees\/educational grants from Medtronic, Biotronik, Abbott, and Philips\/Spectranetics without impact on his personal remuneration. He serves as a proctor for Medtronic. Research grants from the Swiss National Science Foundation, the Swiss Innovation agency Innosuisse, the Swiss Heart Foundation, the University of Bern, the University Hospital Bern, the Velux Foundation, the Hasler Foundation, the Swiss Heart Rhythm Foundation, and the Novartis Research Foundation. He is Co-founder and CEO of Act-Inno AG. F. N.: Medtronic, Abbott: Travel fees, speaker fees, educational grant; Boston Scientific, Philips Spectranetics: Travel fees, educational grant; Biotronik: Institutional grant all for work outside the submitted study. L. R.: Speaker honoraria from Abbott\/SJM, consulting honoraria from Medtronic, and a research grant to the institution for an investigator-initiated trial from Medtronic. T. R.: Research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, and the sitem insel support funds, all for work outside the submitted study. Speaker\/consulting honoraria or travel support from Abbott\/SJM, Biosense-Webster, Biotronik, Boston-Scientific and Medtronic, all for work outside the submitted study. Support for his institution\u2019s fellowship program from Abbott\/SJM, Biosense-Webster, Biotronik, Boston-Scientific, and Medtronic for work outside the submitted study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}